Congress Navigator
All HCPs
11

HCP 11

Medical Oncologist · Germany · Department head

Illustrative synthetic data for prototype demonstration — not real clinical findings.

Discussion summary

Sees a clear unmet need; enthusiastic where benefit magnitude is convincing.

Key themes

Unmet needMagnitude of benefit

Pre / post perception

Overall perception shift

Pre-congress vs post-congress

4 improved

Perception of clinical efficacy

Neutral
Positive
+1

Confidence in the evidence

Positive
Positive
0

Safety / tolerability perception

Low
Neutral
+1

Likelihood to prescribe

Neutral
Positive
+1

Familiarity with treatment

Positive
Very positive
+1

Competitive perception

Low
Low
0

Illustrative synthetic measures. Movement is shown as an observed pre/post shift, not a causal effect of the congress.

KBQs discussed

Position against each predefined question

Clinical significance of the primary endpoint

What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?

Supportive
“The effect size here is hard to ignore — for the patients I see this is a genuinely meaningful result.”
See aggregated KBQ finding

Safety, tolerability and willingness to prescribe

How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?

High willingness
“Nothing here is unfamiliar; managing these events is part of routine class experience.”
See aggregated KBQ finding

Use in node-positive populations

What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?

Favourable
“These higher-risk patients are exactly who I would prioritise.”
See aggregated KBQ finding

Sequencing after adjuvant recurrence

How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?

Individualised
“Increasingly I let the molecular findings guide what I choose next.”
See aggregated KBQ finding

Compelling nature of the primary endpoint

How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?

Compelling
“The effect relative to the comparators is enough to make this my first choice.”
See aggregated KBQ finding

Perception of safety and tolerability

How do experts perceive the safety and tolerability profile demonstrated in the trial?

Favourable
“No new signal emerged, which is reassuring.”
See aggregated KBQ finding